| Literature DB >> 25004418 |
Pedro Beraldo de Andrade1, Mônica Vieira Athanazio de Andrade1, Robson Alves Barbosa1, André Labrunie1, Mauro Esteves Hernandes2, Roberto Luiz Marino3, Dalton Bertolim Precoma4, Francisco Carleial Feijó de Sá5, Otávio Berwanger6, Luiz Alberto Piva e Mattos7.
Abstract
BACKGROUND: The radial access provides a lower risk of bleeding and vascular complications related to the puncture site in comparison to the femoral access. Recent studies have suggested a reduction in mortality associated with the radial access in patients with acute myocardial infarction undergoing percutaneous coronary intervention.Entities:
Mesh:
Year: 2014 PMID: 25004418 PMCID: PMC4079020 DOI: 10.5935/abc.20140063
Source DB: PubMed Journal: Arq Bras Cardiol ISSN: 0066-782X Impact factor: 2.000
Baseline clinical characteristics and demographics
|
|
|
|
|
|
|---|---|---|---|---|
| Age, mean ± standard deviation | 61.8 ± 12.3 | 63.1 ± 12.3 | 58.9 ± 11.7 | < 0.001 |
| Male gender, n (%) | 442 (75.2) | 300 (73.2) | 142 (79.8) | 0.097 |
| Female gender, n (%) | 146 (24.8) | 110 (26.8) | 36 (20.2) | 0.097 |
| Systemic hypertension, n (%) | 395 (67.2) | 279 (68.0) | 116 (65.2) | 0.505 |
| Diabetes mellitus, n (%) | 142 (24.1) | 97 (23.7) | 45 (25.3) | 0.676 |
| Dyslipidemia, n (%) | 278 (47.3) | 203 (49.5) | 75 (42.1) | 0.106 |
| Obesity, n (%) | 187 (31.8) | 132 (32.2) | 55 (30.9) | 0.773 |
| Smoking habit, n (%) | 185 (31.5) | 115 (28.0) | 70 (39.3) | 0.009 |
| Previous acute myocardial infarction (%) | 121 (20.6) | 91 (22.2) | 30 (16.9) | 0.150 |
| Previous stroke, n (%) | 47 (7.9) | 27 (6.6) | 20 (11.2) | 0.068 |
| Chronic kidney failure, n (%) | 17 (2.9) | 15 (3.7) | 2 (1.1) | 0.111 |
Characteristics of the procedures and in-hospital antithrombotic therapy
|
|
|
|
|
|
|---|---|---|---|---|
| Procedural success rate, n (%) | 568 (96.6) | 397 (96.8) | 171 (96.1) | 0.627 |
| Stent implantation, n (%) | 562 (98.9) | 395 (99.5) | 167 (97.7) | 0.192 |
| Drug-eluting stent, n (%) | 126 (21.4) | 116 (28.3) | 10 (5.6) | < 0.001 |
| Non-drug-eluting stent, n (%) | 436 (74.1) | 279 (68.0) | 157 (88.2) | < 0.001 |
| One-vessel, n (%) | 275 (48.5) | 197 (49.1) | 78 (47.0) | 0.369 |
| Two-vessel, n (%) | 172 (30.3) | 131 (32.7) | 41 (24.7) | 0.030 |
| Multivessel, n (%) | 111 (19.6) | 69 (17.2) | 42 (25.3) | 0.066 |
| Acetylsalicylic acid, n (%) | 578 (98.3) | 405 (98.8) | 173 (97.2) | 0.179 |
| Clopidogrel, n (%) | 561 (95.4) | 395 (96.3) | 166 (93.3) | 0.131 |
| Prasugrel, n (%) | 4 (0.7) | 4 (100.0) | 0 (0.0) | 0.320 |
| Ticagrelor, n (%) | 7 (1.2) | 1 (0.2) | 6 (3.4) | 0.004 |
| Glycoprotein IIb-IIIa inhibitors, n (%) | 105 (17.9) | 61 (14.9) | 44 (24.7) | 0.005 |
| Unfractioned heparin, n (%) | 101 (17.2) | 83 (20.2) | 18 (10.1) | 0.003 |
| Enoxaparin, n (%) | 377 (64.1) | 261 (63.7) | 116 (65.2) | 0.779 |
| Fondaparinux, n (%) | 31 (5.3) | 6 (1.5) | 25 (14.0) | < 0.001 |
Graph 1Clinical endpoints (%) at six months of follow-up.